SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Overweight
- Sponsor
- Maastricht University Medical Center
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Background of the study:
A sedentary lifestyle and obesity are well known risk factors of type 2 diabetes. The major focus of current guidelines for type 2 diabetes prevention is on energy balance. Physical activity guidelines recommend at least 30 minutes/day of moderate to vigorous physical activity (MVPA). However, no advice is given how the other 23.5 hours of the day should be spent. Several recent epidemiologic studies suggest that excessive sitting, independent of moderate to vigorous physical activity, has detrimental health effects. Another possibility to sit less is by increasing low intensity physical activities as slowly walking and standing. A recent published study of Duvivier and colleagues suggests that sitting less and replacing it by slowly walking and standing has a better effect on insulin action and cardiovascular risk factors than the combination of one hour MVPA per day and sitting the rest of the day in healthy subjects (Duvivier et al. PLOS ONE 2013). Until now this research is not performed in subjects with overweight/obesity.
Objective of the study:
To assess the effect of low intensity physical activity on plasma insulin levels, cognition and mood in subjects with overweight/obesity
Study population:
21 subjects between 40-80 years old with overweight/obesity
Intervention:
2 activity regimes of 4 days: a sitting regime and a "sit less" regime
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Men and postmenopausal women: 40-80 years old
- •BMI: 25.0 - 35.0 kg/m2
- •Maximum 2.5 hours of MVPA per week (during last 3 months)
- •Having a general practitioner
- •Agreeing to be informed about medically relevant personal test-results by a physician
- •Accessible veins on arms as determined by examination at screening
Exclusion Criteria
- •Reported participation in another biomedical trial which may have an effect on insulin sensitivity one month before the pre-study examination or during the study
- •Blood donation in the past three months
- •Reported participation in night shift work 2 weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM.
- •Consumption of \>14 (women) or \> 21 (men) alcoholic units per week
- •Reported dietary habits: medically prescribed diet, slimming diet;
- •Reported weight loss (\>2kg) in the last three months prior to the screening;
- •Not being able to execute at least three (out of four) cognition tests in the training session
- •Not being able to execute the sit less try-out day
- •Being an employee of Unilever or the collaborating research departments in Maastricht University Medical Centre
- •Experimental drug use (during the last 3 months)
Outcomes
Primary Outcomes
Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)
Time Frame: one day after each regime
To assess the effect of low intensity physical activity (LIPA) on plasma insulin levels (as measured as area under the curve during an oral glucose tolerance test)
Secondary Outcomes
- Plasma total cholesterol(one day after each regime)
- Plasma C-peptide(one day after each regime)
- Plasma triglycerides(one day after each regime)
- Plasma non-HDL cholesterol(one day after each regime)
- Attention (measured by the Attention Network Task)(one day after each regime before and after the oral glucose tolerance test)
- Memory (measured by the Rey Auditory Verbal Learning Task)(one day after each regime before and after the oral glucose tolerance test)
- Plasma interleukin 1(one day after each regime)
- Insulin sensitivity (measured as Matsuda combined insulin sensitivity index during an oral glucose tolerance test)(one day after each regime)
- Plasma glucose levels(one day after each regime)
- Plasma apolipoprotein A(one day after each regime)
- Mood (measured by the Affect Grid mood scale)(2 days: last day of each regime and one day after each regime)
- Plasma TNF-alpha(one day after each regime)
- Plasma interferon gamma(one day after each regime)
- Plasma E-selectine(one day after each regime)
- Plasma von Willebrand factor (vWF)(one day after each regime)
- Blood pressure(one day after each regime)
- Plasma HDL cholesterol(one day after each regime)
- Plasma LDL cholesterol(one day after each regime)
- Plasma free fatty acids(one day after each regime)
- Plasma apolipoprotein B(one day after each regime)
- Plasma ICAM-1(one day after each regime)
- Plasma VCAM(one day after each regime)
- To explore the association between plasma glucose, plasma insulin, insulin sensitivity and mood, cognitive performance, quality of life and sleep(one day after each regime)
- Executive Function (measured by the Trail Making Test)(one day after each regime before and after the oral glucose tolerance test)
- Quality of life (measured by the Gill 32-item questionnaire)(last day of each regime)
- Sleep (measured by the 10-item Pittsburgh Sleep Quality Index)(last day of each regime)
- Plasma C-reactive protein(one day after each regime)
- Plasma serum amyloid A (SAA)(one day after each regime)
- Plasma PAI-1(one day after each regime)
- Plasma interleukin 6(one day after each regime)
- Heart rate(one day after each regime)